Skip to main content
. Author manuscript; available in PMC: 2025 Aug 25.
Published in final edited form as: Stat Biopharm Res. 2024 Jan 5;17(1):36–45. doi: 10.1080/19466315.2023.2288013

Table 1:

Simulated trial of complete information

Patient Latent Pr (C-DLT) at Latent Pr (P-DLT) at
Number C-DLT dose level xj P-DLT dose level xj
k v1j 0.05 0.05 0.25 0.40 0.55 v2j 0.17 0.18 0.35 0.50 0.65
1 0.04 1 1 1 1 1 0.85 0 0 0 0 0
2 0.98 0 0 0 0 0 0.46 0 0 0 1 1
3 0.31 0 0 0 1 1 0.37 0 0 0 1 1
4 0.71 0 0 0 0 0 0.41 0 0 0 1 1
5 0.43 0 0 0 0 1 0.19 0 0 1 1 1
6 0.24 0 0 1 1 1 0.56 0 0 0 0 1
7 0.47 0 0 0 0 1 0.27 0 0 1 1 1
8 0.54 0 0 0 0 1 0.13 1 1 1 1 1
9 0.48 0 0 0 0 1 0.91 0 0 0 0 0
10 0.28 0 0 0 1 1 0.71 0 0 0 0 0
11 0.76 0 0 0 0 0 0.67 0 0 0 0 0
12 0.14 0 0 1 1 1 0.36 0 0 0 1 1
13 0.97 0 0 0 0 0 0.45 0 0 0 1 1
14 0.60 0 0 0 0 0 0.70 0 0 0 0 0
15 0.06 0 0 1 1 1 0.89 0 0 0 0 0
16 0.13 0 0 1 1 1 0.48 0 0 0 1 1
17 0.97 0 0 0 0 0 0.21 0 0 1 1 1
18 0.46 0 0 0 0 1 0.49 0 0 0 1 1
θˆ1j 0.06 0.06 0.28 0.39 0.67 θˆ2j 0.06 0.06 0.22 0.61 0.67